


## Seeking Novel Anti-tumour Antibodies

Xencor is a clinical-stage biopharmaceutical company focused on the **discovery and development of bispecific antibodies** and cytokine drugs. Xencor is currently seeking **monoclonal antibodies directed against tumour-associated antigens**, for incorporation into their clinically validated **T cell engager** platform.



### Approaches of Interest

- The highest priority is given to **novel, solid tumour targets**
- There is also interest in **antibodies against well-known tumour targets** but with **novel/differentiated epitopes**
- **Targets expressed specifically on tumour cells** are of the highest interest, with stromal targets are still of interest
- Cancers of interest include but are not limited to **ovarian, breast (especially TNBC), head and neck, lung, colon, prostate, kidney, oesophageal, bladder and liver**
- **Key data sets should include:** Tumour vs normal expression (RNA and/or immunohistochemistry), antibody affinity and selectivity, and antibody binding to representative tumour cell lines

### Out of scope

- Pancreatic and haematological cancers
- Checkpoint inhibition and activation of the complement system
- Antibody delivery methods and platform technologies for antibody production

### Developmental Stages of Interest

- Xencor is open to approaches from the discovery stage through to clinical Phase II, with a particular interest in opportunities at the discovery/preclinical stage
- Opportunities with *in vivo*, *in vitro* and/or *ex vivo* validation will be accepted






### Submission Information

Submission of one page, 200-300 word briefs are encouraged. Along with any optional supplementary information e.g. relevant publications and patents. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

### Opportunity for Collaboration

Xencor is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, research collaborations and sponsored research opportunities.

#### Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Research projects
-  Spinout companies

#### Submissions

Please submit relevant, non-confidential opportunities online via: [discover.in-part.com](https://discover.in-part.com)

Deadline: **6th June 2022 - 10:59 pm GMT**

#### Have any questions?

Contact our team at [discover@in-part.co.uk](mailto:discover@in-part.co.uk)

